Page last updated: 2024-11-12

miv 150

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MIV 150: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9907284
CHEMBL ID	391735
SCHEMBL ID	3732549
MeSH ID	M0498051

Synonyms (24)

Synonym
miv-150
CHEMBL391735 ,
1-(5-cyano-2-pyridyl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoyl-phenyl)cyclopropyl]urea
miv150
urea, n-[(1s,2s)-2-[6-fluoro-2-hydroxy-3-(1-oxopropyl)phenyl]cyclopropyl]-n'-(5-cyano2-pyridinyl)-
824vsi942y ,
pc 815
231957-54-3
miv 150
1-(5-cyanopyridin-2-yl)-3-((1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl)urea
unii-824vsi942y
SCHEMBL3732549
pc-815
urea, n-(5-cyano-2-pyridinyl)-n'-((1s,2s)-2-(6-fluoro-2-hydroxy-3-(1-oxopropyl)phenyl)cyclopropyl)-
pc-1005 component miv-150
miv-150 component of pc-1005
DTXSID70177773
bdbm50477159
CS-0015478
HY-19378
miv-1r
Q27269302
1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
AKOS040742143

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Adverse events, which were primarily mild and/or unrelated, were comparable between groups."	( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics. Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016)	0.43

Pharmacokinetics

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were calculated using noncompartmental techniques and actual sampling times."	( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics. Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016)	0.43

Dosage Studied

Excerpt	Relevance	Reference
" CVL antiviral EC50 values were calculated using a dose-response inhibition analysis."	( First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics. Alami, M; Creasy, GW; Fernández-Romero, JA; Friedland, BA; Hoesley, CJ; Hoskin, E; Katzen, LL; Kleinbeck, KR; Novak, L; Plagianos, M; Teleshova, N; Zhang, S; Zydowsky, TM, 2016)	0.43

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Kd	0.0020	0.0006	2.4059	9.8000	AID301920; AID301921; AID301922; AID301923; AID301924; AID301925; AID301926; AID301927
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID301922	Binding affinity to HIV1 reverse transcriptase K103N mutant at 25 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301921	Binding affinity to HIV1 reverse transcriptase K103N mutant at 15 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301920	Binding affinity to HIV1 reverse transcriptase K103N mutant at 5 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301926	Binding affinity to HIV1 reverse transcriptase Y181C mutant at 25 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301923	Binding affinity to HIV1 reverse transcriptase K103N mutant at 35 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301924	Binding affinity to HIV1 reverse transcriptase Y181C mutant at 5 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301927	Binding affinity to HIV1 reverse transcriptase Y181C mutant at 35 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
AID301925	Binding affinity to HIV1 reverse transcriptase Y181C mutant at 15 degC	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (16.67)	29.6817
2010's	19 (79.17)	24.3611
2020's	1 (4.17)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	17.10 (24.57)
Research Supply Index	3.30 (2.92)
Research Growth Index	5.21 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (17.10)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (8.33%)	5.53%
Reviews	1 (4.17%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	3.16	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	7.66	24	2	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.03	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.03	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
thiazoles [no description available]	2.07	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.52	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.03	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.62	2	0	1,2,3-triazole
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	3.16	1	0	divalent inorganic anion; phosphite ion
dapivirine Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission	3.6	2	0
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.59	2	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.07	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
maraviroc [no description available]	3.16	1	0	tropane alkaloid
rilpivirine [no description available]	2.15	1	0	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
doravirine [no description available]	2.25	1	0

Condition	Relationship Strength	Studies	Trials
HIV Coinfection [description not available]	5.78	7	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	5.78	7	1
Genital Tract Infections [description not available]	2.15	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.15	1	0
Herpes Simplex Virus Infection [description not available]	2.78	3	0
AIDS, Simian [description not available]	3.96	12	0
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	2.78	3	0
HPV Infection [description not available]	2.51	2	0
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	2.51	2	0
Monkey Diseases Diseases of Old World and New World monkeys. This term includes diseases of baboons but not of chimpanzees or gorillas (= APE DISEASES).	2.11	1	0
Genital Herpes [description not available]	4.18	3	1
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	4.18	3	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.11	1	0
Co-infection [description not available]	3.51	1	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.48	2	0
Sexually Transmitted Disease, Viral [description not available]	3.51	1	1

chemdatabank.com